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We conducted a retrospective cohort study to investigate the predisposing factors for local recurrence 
and complications after percutaneous radiofrequency ablation (RFA) of hepatocellular carcinoma 
(HCC).  HCC patients (n＝397) consecutively treated with RFA (256 males,  141 females,  median age 69 
years) were enrolled.  In these patients,  1,455 nodules (median size 17mm) were ablated.  Predisposing 
factors for overall recurrence and local recurrence in the context of tumor location and complications 
were examined.  Local recurrence was observed for 113 of the 1,455 nodules.  The 1-,  3- and 5-year 
local recurrence rates were 2.2ｵ,  7.4ｵ and 9.5ｵ,  respectively.  A multivariate Cox proportional 
hazard analysis revealed that large tumor size (＞2cm),  tumor location (adjacent to the major portal 
branch or hepatic vein),  and small ablated margin (＜3mm) were independent predisposing factors for 
local recurrence after RFA (HR＝1.70-2.81).  Tumor location (adjacent to the major portal branch,  
hepatic vein,  or diaphragm) was also revealed as a risk factor for liver damage due to RFA.  HCC 
adjacent to the major portal vein or hepatic vein was associated with a higher risk for local recur-
rence and for complications; therefore,  special precautions are necessary when applying RFA to HCC 
near vessels even when the tumors are located at an easy-to-puncture site.
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epatocellular carcinoma (HCC) is the most fre-
quent primary hepatic malignancy and has been 
recognized as the major cause of death in cirrhotic 
patients.  Epidemiological data indicate that the preva-
lence of HCC is increasing in the United States and 
Europe [1-3].  Early detection programs including 
periodic imaging surveillance with ultrasonography 
(US) or computed tomography (CT) and periodic 
measurements of serum tumor markers such as alpha-
fetoprotein (AFP) and des-gamma-carboxy prothrom-
bin (DCP) have increased the number of HCC patients 
suitable for curative treatment.  Surgical resection 
nevertheless plays a limited role in the treatment of 
many HCC cases because of liver dysfunction caused 
by coexisting cirrhosis or the presence of multiple 
tumors [4,  5].  Moreover,  HCC often recurs even 
after systematic resection of the tumor-bearing liver,  
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and liver transplantation can only be oﬀered to a lim-
ited number of patients due to the shortage of donors.
　 Various types of nonsurgical treatments have been 
developed.  Radiofrequency ablation (RFA) can achieve 
complete tumor necrosis [6-8] and has become a 
principal treatment in many institutions for patients 
with small HCCs.  The rate of recurrence of HCC 
after curative treatment including RFA is high: Rossi 
et al.  reported a cure rate as high as 70ｵ over a 
3-year period [9].
　 Many studies have been performed to elucidate risk 
factors for the recurrence of HCC.  Large tumor size,  
high tumor number,  high AFP level,  and low albumin 
are frequently noted as risk factors [11-17]; how-
ever,  most of these risk factors were associated with 
distant recurrence,  and the risk of local recurrence 
has not been elucidated.  We previously reported the 
risk factors for HCC recurrence after local ablation 
therapy,  and our ﬁndings demonstrated that the fac-
tors for local and distant recurrence were completely 
diﬀerent [10].  At that time,  the majority of the 
patients in the study has been treated with percutane-
ous ethanol injection therapy.  Several studies were 
later published analyzing the risk factors for local 
recurrence after RFA,  and in those studies,  tumor 
size,  tumor location (subcapsular or blood vessel 
proximity),  ablated margins,  and HBV viral load were 
noted as risk factors for local recurrence; however,  
the factors varied from one report to another [11-
17].
　 In the present study,  we analyzed the risk factors 
for local recurrence in Japanese HCC patients treated 
with the latest percutaneous RFA technique in con-
junction with artiﬁcial ascites/pleural eﬀusion,  and 
our analysis included precise information about the 
location of the tumor(s) and any resulting complica-
tions.
Materials and Methods
　 Patients and tumors. Among the 849 con-
secutive patients with newly diagnosed HCC between 
April 2001 and July 2011 at Okayama University 
Hospital,  397 patients who were treated with RFA as 
an initial therapy for HCC were enrolled in this study.  
During this period,  we treated 1,455 HCCs within this 
cohort of 397 patients.  Therapies were selected 
according to the evidence-based clinical practice 
guidelines for HCC in Japan [18].
　 Informed consent to analyze the data was obtained 
from all patients.  The study protocol conformed to the 
ethical guidelines of the World Medical Association 
and the Declaration of Helsinki,  and was approved by 
the Hospitalʼs Ethical Committee.
　 Diagnosis of HCC. HCC diagnosis was con-
ﬁrmed histologically in 103 patients who had under-
gone ultrasound (US)-guided biopsy.  The remaining 
294 patients were diagnosed via typical HCC image 
patterns obtained by angiography,  CT,  magnetic 
resonance (MR) imaging,  and US.  The diagnostic 
criteria of HCC by imaging modalities were based on 
previous reports of hyper-attenuation at the hepatic 
arterial phase,  hypo-attenuation at the portal venous 
phase in triple-phase CT or MR imaging,  and tumor 
stain on angiography,  or hyper-enhancement in the 
arterial phase,  hypo-enhancement in the portal venous,  
and late phases in contrast-enhanced US [19-21].
　 Tumor vascularity was deﬁned as ʻhyper-vascularʼ 
when the tumor showed hyper-attenuation at the 
hepatic arterial phase by CT or MR imaging,  or 
hyper-enhancement in the arterial phase by contrast-
enhanced US.
　 We also checked the location of tumors,  and if a 
tumor was located within 5mm from other organs or 
vessels,  we deﬁned the tumor as ʻadjacent.ʼ
　 Treatment methods. Patients with HCCs that 
appeared hyper-attenuated at the hepatic arterial 
phase in dynamic CT or MR imaging underwent super-
selective transcatheter arterial chemoembolization 
(TACE) at least 1wk prior to RFA (n＝663,  46ｵ).  
We skipped TACE in several cases when the tumors 
were small and we judged that the tumors might 
become hard to detect by US.  Epirubicin hydrochlo-
ride (Farmorbicin; Pharmacia,  Tokyo,  Japan) with 
iodized oil (Lipiodol Ultraﬂuid; TERUMO,  Tokyo,  
Japan) followed by embolization with gelatin particles 
(Gelpart,  Nippon Kayaku,  Tokyo,  Japan) or miripla-
tin hydrate (Milipra,  Dainippon Sumitomo Pharma,  
Osaka,  Japan) was used for chemoembolization [22].
　 RFA was performed under US guidance as 
described [10,  22].  A 17-gauge internally cooled-tip 
electrode (20-cm long with a 2- or 3-cm-long exposed 
metallic tip) and a 480-kHz monopolar RF generator 
(Covidien Japan,  Tokyo,  Japan) were used for abla-
tion.  When the diameter of the HCC was＜1.5cm,  a 
2-cm-long exposed metallic tip was usually used.  A 
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3-cm-long exposed tip was used in the rest of the 
cases.  After the tumor was penetrated with the elec-
trode,  the generator was set to the impedance mode 
and the output was increased stepwise from 60 W for 
a 3-cm-exposed tip (40 W for a 2-cm-exposed tip) until 
it reached maximum power or was impeded out (10-
20-W increase per min).  After it was impeded out,  the 
power was decreased by 10-20 W,  and the ablation 
was continued for 10-12min (6-10min for a 2-cm-
exposed tip).  We repeated the RFA until the 
microbubbles covered the area expected to include the 
entire tumor.
　 When the targeted nodule was adjacent to the dia-
phragm or was not clearly seen because of the lung 
artifact,  we used the artiﬁcial pleural eﬀusion tech-
nique to prevent lung injury (for 368 nodules).  If the 
targeted nodule was close to the gastrointestinal tract,  
we used the artiﬁcial ascites technique (for 142 nod-
ules).  To control pain,  15-30mg of pentazocine and 
25mg of hydroxyzine were administered intravenously 
to each patient.
　 The therapeutic eﬀectiveness was assessed with 
contrast-enhanced CT or MRI performed 3-5 days 
after the RFA treatment to conﬁrm that the entire 
tumor was covered within the ablated area.  All images 
were reviewed by 2 radiologists and 2 hepatologists.  
To determine the “ablative margin,” we measured the 
minimal distance between the tumor edge and the 
ablated area that was deﬁned as a nonenhanced area at 
the portal venous phase of triple-phase CT or MRI.
　 In cases of residual viable lesion,  an additional 
RFA treatment was performed (122 nodules).
　 Follow-up. After treatment,  the patients were 
assessed approximately every 2 or 3 months by US,  
triple-phase CT,  or MR imaging.  Local recurrences 
were deﬁned as the appearance of tumors adjacent to 
(in contact with) the ablated lesion.  Patients were 
followed up until the date of last follow-up or death.  
The median follow-up period per patient was 55.7 
months (interquartile range,  33.0-79.3 months).  
Complications were reported according to version 4.0 
of the U.S.  National Cancer Instituteʼs Common 
Terminology Criteria for Adverse Events.  We con-
sidered events equal to or above grade 2 as complica-
tions.  We did not take pain into account as a compli-
cation because most of the patients claimed moderate 
pain during the procedure and mild pain at the punc-
ture site for 3-4days.
　 Complications were divided into 5 categories: liver 
injury (i.e.,  ascites,  pleural eﬀusion,  hepatic infarc-
tion,  and/or portal vein thrombosis),  hemorrhage (i.e.,  
injury of the intracostal artery or hemorrhage to the 
outside of the liver),  biliary damage (i.e.,  biloma or 
bile duct stenosis),  cardiovascular damage (i.e.,  vago-
tonia,  paroxysmal atrial tachycardia,  or paroxysmal 
atrial ﬁbrillation),  and “other.” Complications that 
might induce or be induced by the deterioration of 
liver function were categorized as “liver injury.”
　 Statistical analysis. Quantitative variables such 
as clinical background variables are presented as 
median values and interquartile range,  and qualitative 
variables are presented as absolute and relative fre-
quencies.  Survival probabilities were estimated by the 
Kaplan-Meier method.  The parameters for the uni-
variate and multivariate analyses of patient and tumor 
characteristics included age,  gender,  Child-Pugh 
grade,  number of tumors,  tumor size,  vascularity of 
the tumor,  tumor location (adjacent to large vessels 
such as the hepatic vein,  portal vein,  or inferior vena 
cava; adjacent to extrahepatic organs such as the 
diaphragm,  heart,  kidney,  stomach,  colon,  pancreas,  
or gall bladder),  tumor markers,  and ablated margin.  
We classiﬁed the portal vein into 2 groups: major 
branch and minor branch.  “Major branch” included the 
main trunk and ﬁrst- or second-order branches of the 
portal vein,  and “minor branch” were vessels distal to 
the third-order branch of the portal vein.
　 Variables associated with recurrence and compli-
cations were assessed by the Cox proportional hazard 
model and logistic regression model,  respectively.  
Variables with a p-valueｦ0.05 in a univariate com-
parison were subjected to the multivariate analysis.  
All signiﬁcance tests were two-sided,  and diﬀerences 
with a p-value＜0.05 were considered signiﬁcant.  All 
statistical analyses were performed using JMP soft-
ware,  version 11.2 (SAS Institute,  Tokyo,  Japan).
Results
　 Patient characteristics. The clinical features 
of the 397 patients are shown in Table 1.  The patient 
cohort consisted of 256 males and 141 females with a 
median age of 69 years,  including 328 cases of Child-
Pugh grade A hepatic impairment.  The majority of the 
patients (n＝328,  82.6ｵ) were positive for hepatitis 
C virus antibody.  The median size of the tumor was 
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17mm,  and 254 patients (64ｵ) had a single tumor.
　 The 1-,  3- and 5-year survival rates of the 
patients with primary HCC were 97.4ｵ,  85.3ｵ,  and 
70.1ｵ,  respectively.
　 Predisposing factors for recurrence.
Recurrence of HCC was observed in 269 patients 
(67.7ｵ).  The 1-,  3- and 5-year recurrence rates were 
23.8ｵ,  56.2ｵ,  and 68.0ｵ,  respectively (Fig.  1).  
The univariate analysis revealed that low platelet 
count (＜1.00×105/µL),  high AFP (ｧ100ng/mL),  
high DCP (ｧ40mAU/mL),  multiple nodules,  and 
large tumor size (＞2cm) were predisposing factors 
for recurrence.  Low platelet count,  high DCP,  and 
multiple nodules were selected as signiﬁcant factors 
for the multivariate analysis (Table 2).
　 Predisposing factors for local recurrence.
Between April 2001 and July 2011,  we used RFA to 
treat 1,455 HCCs in the 397 patients.  We failed to 
complete ablation for 21 nodules (1.4ｵ).  The residual 
lesions of these tumors were treated with TACE when 
those tumors enlarged.
　 We used the 2-cm-long exposed tip for 1,166 
tumors and the 3-cm-long exposed tip for the rest of 
the tumors.  The median (interquartile range) sizes of 
those tumors were 12mm (10-15mm) and 21mm (17-
25mm),  respectively (p＜0.0001).
　 Predisposing factors for local recurrence were 
examined (Table 3).  Two hundred ﬁfty-nine nodules 
(17.8ｵ) were adjacent to large vessels and 520 nod-
ules (35.7ｵ) were adjacent to extrahepatic organs 
including the diaphragm,  gastrointestinal tract,  heart,  
kidney,  pancreas,  and gall bladder.  Recurrences were 
observed for 113 nodules,  and the 1-,  3- and 5-year 
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Table 1　 Patient data and characteristics
Number of patients 397
Age,  years 69 (62-74)
Gender (male/female) 256/141
Etiology (HCV/HBV/HCV and HBV/other) 320/37/8/32
Child-Pugh grade (A/B/C) 328/66/3
Serum bilirubin,  mg/dL 0.82 (0.63-1.11)
Serum albumin,  g/dL 3.7 (3.3-4.0)
Prothrombin time,  % 92 (82-103)
Platelet count×105/µL 1.05 (0.73-1.50)
AFP,  ng/mL 13.3 (5.8-43.1)
AFP-L3,  % 0.5 (0-1.7)
DCP,  mAU/mL 28 (19-62)
Number of nodules (1/2/3/4-) 254/82/37/24
Maximum tumor diameter,  mm 17 (13-21)
All variables are reported as the median (interquartile range).
HCV,  hepatitis C virus; HBV,  hepatitis B virus; AFP,  alpha-
fetoprotein; AFP-L3,  lectin-bound alpha-fetoprotein; DCP,  des-
gamma-carboxy prothrombin.
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Fig. 1　 Cumulative overall recurrence rates of hepatocellular carcinoma (HCC) after radiofrequency ablation (RFA) therapy.  The 1-,  3- 
and 5-year recurrence rates were 23.8%,  56.2%,  and 68.0%,  respectively.
local recurrence rates were 2.2ｵ,  7.4ｵ,  and 9.5ｵ,  
respectively (Fig.  2).
　 The univariate analysis revealed that large tumor 
size (＞2cm),  tumor location (adjacent to the major 
portal branch or hepatic vein),  and small ablated 
margin (＜3mm) were signiﬁcant predisposing factors 
223Local Recurrence after RFAAugust 2015
Table 2　 The predisposing factors for HCC recurrence after RFA
Patient characteristics
Hazard ratio (95% C.I.)
Univariate P value Multivariate P value
Ageｧ70 years 1.08 (0.85-1.37) 0.54
Gender (male) 1.13 (0.88-1.45) 0.35
Etiology (HCV) 1.27 (0.93-1.78) 0.13
Etiology (HBV) 0.82 (0.55-1.18) 0.30
Child-Pugh grade (B or C) 0.94 (0.67-1.30) 0.72
Platelet count (＜1.00×105/µL) 1.43 (1.12-1.82) 0.0036 1.40 (1.09-1.78) 0.0078
AST＞80 IU/L 0.90 (0.64-1.23) 0.52
ALT＞80 IU/L 0.96 (0.67-1.32) 0.80
AFPｧ100ng/mL 1.43 (1.01-1.97) 0.044 1.17 (0.82-1.64) 0.40
AFP-L3ｧ10% 1.45 (0.96-2.10) 0.073
DCPｧ40mAU/mL 1.43 (1.12-1.83) 0.0050 1.34 (1.02-1.74) 0.035
Multiple nodules 1.45 (1.13-1.85) 0.0037 1.40 (1.09-1.80) 0.0096
Tumor diameter＞20mm 1.44 (1.11-1.87) 0.0070 1.25 (0.94-1.65) 0.13
HCC,  hepatocellular carcinoma; RFA,  radio-frequency ablation; C.I.,  conﬁdence interval; HCV,  hepatitis C virus; HBV,  hepatitis B 
virus; AFP,  alpha-fetoprotein; AFP-L3,  lectin-bound alpha-fetoprotein; DCP,  des-gamma-carboxy prothrombin.
Table 3　 The predisposing factors for local recurrence after RFA
Risk ratio (95% C.I.)
Univariate P value Multivariate P value
Number of tumors 1,455
Tumor characteristics
　Maximum diameter (＞20mm) 172 (12) 2.17 (1.37-3.33) 0.0015 1.84 (1.15-2.84) 0.011
　Hyper-vascular,  n (%) 1,088 (75) 1.56 (1.00-2.55) 0.052
　TACE prior to RFA,  n (%) 663 (46) 1.10 (0.76-1.60) 0.61
　Tumor form (simple nodular type/others) 1,424/32 1.27 (0.31-3.38) 0.69
Tumor location (adjacent to; )
　Liver surface (hump) 221 0.74 (0.41-1.25) 0.28
　Portal vein (major branch) 92 4.67 (2.91-7.21) ＜0.001 2.91 (1.77-4.61) ＜0.0001
　Portal vein (minor branch) 167 1.38 (0.78-2.27) 0.24
　Hepatic duct 14 3.11 (0.76-8.23) 0.10
　Hepatic vein 143 2.66 (1.67-4.09) ＜0.001 1.92 (1.19-2.99) 0.0082
　IVC 24 1.72 (0.42-4.57) 0.39
　Gall bladder 49 2.10 (0.88-4.18) 0.088
　Colon 42 0.58 (0.10-1.82) 0.40
　Pancreas 12 5.50×10-9 0.18
　Heart 77 1.81 (0.92-3.22) 0.084
　Stomach 41 0.27 (0.02-1.21) 0.10
　Diaphragm 326 1.14 (0.75-1.71) 0.53
　Kidney 41 0.31 (0.02-1.40) 0.15
Ablated margin＜3mm 579 2.96 (2.02-4.41) ＜0.001 2.25 (1.50-3.40) ＜0.0001
HCC,  hepatocellular carcinoma; RFA,  radio-frequency ablation; C.I.,  conﬁdence interval; TACE,  transcatheter arterial chemoemboliza-
tion; IVC,  inferior vena cava; major branch,  the main trunk,  ﬁrst or second order branches of the portal vein; minor branch,  distal to third 
order branch of the portal vein.
for local recurrence.  The multivariate analysis revealed 
that all of the signiﬁcant factors in the univariate 
analysis were independent predisposing factors for 
local recurrence after RFA (hazard ratio [HR]＝
1.84-2.91).
　 Adverse events. Fifty-nine complications were 
reported in 53 of the patients (13.2ｵ) (Table 4);  
some patients experienced multiple complications.  No 
risk factors for hemorrhage,  cardiovascular damage,  
or other complications were reported.  However,  tumor 
vascularity (hypervascular) and tumor location (adja-
cent to the major portal branch,  vein,  or diaphragm),  
as well as high DCP and advanced age (ｧ70 year old) 
were risk factors for liver damage (relative risk 
[RR]＝2.32-3.70); tumor location (adjacent to the 
hepatic duct) was the only risk factor for biliary dam-
age (RR＝34.1) (Table 5).
Discussion
　 We performed a retrospective cohort study to 
clarify the risk factors for the local recurrence of 
HCC after RFA using the latest methods including 
artiﬁcial ascites/pleural eﬀusion,  and we report the 
complications in these Japanese HCC patients,  who 
were standard candidates for RFA.  Although the rate 
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Fig. 2　 Local recurrence rates after RFA therapy.  The 1-,  3-,  and 5-year local recurrence rates were 2.2%,  7.4%,  and 9.5%,  respec-
tively.
Table 4　 Complications due to RFA
Number of Patients
Liver injury
　Pleural eﬀusion (due to hypoalbuminemia) 11
　Hepatic infarction 6
　Portal vein thrombosis 6
　Ascites 2
Hemorrhage
　Hemorrhage to the abdominal cavity 5
　Subcutaneous hemorrhage 4
　Hemorrhage to bile duct 1
　Hemorrhage to the retroperitoneal space 1
　Injury of intracostal artery 1
Biliary damage
　Biloma 5
　Bile duct stenosis 4
Cardiovascular damage
　Vagotonia 4
　Paroxysmal atrial tachycardia 1
　Paroxysmal atrial ﬁbrillation 1
Others
　Liver abscess 1
　Pleuritis 1
　Pyothorax 1
　Skin burn 2
　Diaphragmatic hernia 1
　Pneumothorax 1
of local recurrence was low,  it was never zero,  even 
with careful ablation of the tumors.  Our analysis 
revealed that low platelet count,  high DCP,  and 
multiple nodules were the predisposing factors for 
recurrence after RFA overall,  and the factors for 
local recurrence were large tumor size (＞2cm),  
small ablated margin (＜3mm),  and tumor location 
(adjacent to major portal vein or hepatic vein).  Liver 
injury was the major complication of RFA and was 
closely correlated with the tumor location (adjacent to 
the diaphragm and hepatic vein as well as a major 
branch of the portal vein),  the vascularity of the 
tumor,  the DCP level,  and the age of the patient.
　 The reported risks for distant recurrence depend 
mainly on the carcinogenic potential of noncancerous 
tissues and can change according to the development 
of antiviral treatments.  Here we observed that the risk 
of local recurrence was closely related to the location 
of the tumor,  especially the proximity to blood ves-
sels.  Because the patientʼs blood ﬂow reduces the 
elevation of the tumorʼs temperature during the RFA 
procedure,  the incidence of local recurrence was high-
est near the blood vessels.  Although the use of RFA 
in high-risk locations has been reported [23],  our 
data clearly demonstrate that the incidence of recur-
rence was high and the chance of deterioration of liver 
function was increased in such cases.
　 Bleeding is the most dangerous complication when 
it was necessary to puncture an HCC near a large 
vessel.  However,  this complication was extremely 
rare in the present series,  indicating that bleeding 
could be avoided if the puncture is performed properly 
under real-time imaging by US and by excluding 
patients with bleeding tendency as candidates for 
RFA.  In addition,  we ablated the puncture tract after 
tumor ablation to avoid tumor dissemination,  and this 
procedure itself might prevent bleeding.
　 Although our ﬁndings revealed the clinical features 
of local recurrence after RFA,  there were several 
limitations in this study.  One major limitation is that 
this was a retrospective study conducted at a single 
center.  The inclusion criteria,  RFA procedure,  and 
technical skill level could diﬀer depending on the 
hospital; therefore,  there might be small variations in 
the risk factors of local recurrence and complications 
of RFA among hospitals.  Another limitation lies in the 
diﬃculty in performing RFA in balancing the need to 
prevent recurrence with the necessity to avoid liver 
injury,  which may result from too little or too much 
ablation.  Alternative treatments such as stereotactic 
radiation therapy (SRT) or percutaneous ethanol 
injection therapy (PEIT) could thus be another choice 
in these cases.
　 In conclusion,  our analysis identiﬁed predisposing 
factors for local recurrence and complications follow-
ing RFA as a treatment for HCC,  with a focus on the 
tumor location.  Local recurrence as well as the dete-
rioration of liver function after RFA was high when 
the HCC was adjacent to the vessels,  indicating that 
special caution must be used for the treatment of HCC 
near vessels even when the nodule is located at an 
easy-to-puncture site.
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Table 5　 The risk factors for liver injury and biliary damage after RFA
Liver injury Biliary damage
Risk ratio (95% C.I.) P value Risk ratio (95% C.I.) P value
Tumor location Tumor location
　Diaphragm 3.70 (1.71-7.98) 0.0011 　Hepatic duct 34.1 (4.77-160.0) 0.0021
　Portal vein (major branch) 3.32 (1.03-9.12) 0.045
　Hepatic vein 2.95 (1.11-6.99) 0.032
Tumor character
　Hyper-vascular 3.04 (1.06-12.8) 0.038
Patients character
　DCPｧ40mAU/mL 2.32 (1.04-5.29) 0.041
　Ageｧ70 years 2.53 (1.10-6.33) 0.028
Risk ratios (95% C.I.) were calculated with the logistic regression model.
RFA,  radio-frequency ablation; C.I.,  conﬁdence interval; DCP,  des-gamma-carboxy prothrombin; major branch,  the main trunk,  ﬁrst or 
second order branches of the portal vein.
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